Core Viewpoint - The FDA has approved PYLARIFY TruVu, a new formulation of Lantheus' PSMA PET imaging agent, which aims to enhance diagnostic performance and patient access, with a launch expected in Q4 2026 [1][2]. Group 1: Product Details - PYLARIFY TruVu is indicated for PET imaging of PSMA positive lesions in men with prostate cancer suspected of metastasis or recurrence based on elevated PSA levels [1][11]. - The new formulation is designed to improve product stability at higher radioactive concentrations, which will support more efficient manufacturing and distribution [3]. - PYLARIFY TruVu will be introduced on a rolling geographic basis to ensure a smooth transition for customers from the existing PYLARIFY product [4]. Group 2: Clinical Studies and Efficacy - The safety and efficacy of PYLARIFY TruVu were established through pivotal trials OSPREY and CONDOR, which demonstrated significant improvements in diagnostic performance compared to standard imaging [6][7]. - In the OSPREY trial, PYLARIFY showed a median specificity of 96% and nearly three times the positive predictive value (PPV) compared to standard imaging [7]. - The CONDOR trial reported a correct localization rate (CLR) of 85%-87% for PYLARIFY in patients with biochemical recurrent prostate cancer [7]. Group 3: Market Context and Impact - Prostate cancer is the second most common cancer among men in the U.S., with an estimated 334,000 new cases and over 36,000 deaths expected in 2026 [8]. - More than 760,000 patients have undergone PSMA PET scans with PYLARIFY since its approval in May 2021, highlighting the growing demand for advanced diagnostic tools in prostate cancer [5][9]. - The introduction of PYLARIFY TruVu is seen as a response to the increasing incidence of prostate cancer and the need for timely and accurate imaging solutions [5].